Japan issues guidance on developing risk management plans for drugs, biosimilars
This article was originally published in SRA
Executive Summary
The Japanese Pharmaceuticals and Medical Devices Agency has issued final guidance explaining how drug and biotech companies should develop and submit risk management plans (RMPs) to ensure the safety of products in the post-marketing phase1.